MEDASORB TECHNOLOGIES CORPORATION is a publicly traded therapeutic device company that has developed a powerful, patented, blood purification technology that can remove unwanted substances from blood and physiologic fluids to treat a number of diseases. CytoSorb TM , the company s flagship product, was designed as a cytokine filter to reduce potentially deadly cytokine storm in critically ill patients with severe sepsis. CytoSorb s blood compatible polymer beads are highly porous, capturing appropriately sized substances in its pores, while letting larger or smaller substances pass around or through. As blood is pumped through a cartridge of these beads using standard dialysis equipment, cytokines and other toxins are captured by the beads and removed from blood. The purified blood is then returned to the patient. CytoSorb TM has shown preliminary clinical benefit in a small human pilot study treated, control in patients with severe sepsis and is currently being used in an up to patient European Sepsis Trial to treat potentially fatal cytokine storm during severe infection and severe sepsis. CytoSorbents, Inc is the operating subsidiary of MedaSorb Technologies Corporation.
Quote | CytoSorbents Corporation (NASDAQ:CTSO)
Last: | $1.03 |
---|---|
Change Percent: | 3.88% |
Open: | $0.99 |
Close: | $1.03 |
High: | $1.04 |
Low: | $0.9825 |
Volume: | 25,273 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | CytoSorbents Corporation (NASDAQ:CTSO)
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...
2024-07-02 07:06:13 ET More on Cytosorbents CytoSorbents reports regulatory approval of CytoSorb in Taiwan Seeking Alpha’s Quant Rating on Cytosorbents Read the full article on Seeking Alpha For further details see: CytoSorbents gets new $20M credi...
Message Board Posts | CytoSorbents Corporation (NASDAQ:CTSO)
Subject | By | Source | When |
---|---|---|---|
Plus they have a credit line facility in | Good Sport | investorshub | 07/09/2023 9:53:56 PM |
They won't run out of cash. They have | biotech48 | investorshub | 07/08/2023 9:31:48 PM |
When do they run out of cash? | ranchhand71 | investorshub | 07/07/2023 8:44:14 PM |
PR out that we've completed enrollment. | fantomphan | investorshub | 07/07/2023 12:28:30 PM |
Extracorporeal hemoadsorption therapy as a potential therapeutic option | Good Sport | investorshub | 07/07/2023 2:53:18 AM |
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on...
PRINCETON, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the reg...